Billiontoone Inc (BLLN) Stock Forecast & Price Target

BillionToOne is backed by strong fundamentals, with Q3 revenue of $123M rising 47% Y/Y, adjusted EBITDA of $23M, and $562M of cash, while management also lifted 2026 revenue guidance to $460M-$470M. Its outlook is further supported by differentiated technology and commercialization momentum: UNITY’s workflow advantage is driving share gains in prenatal testing, payor coverage now totals about 300M lives, and oncology is growing rapidly with 96% Y/Y revenue growth and 94% agreement in the Northstar Response head-to-head study. The pending December 15, 2026 launch of Northstar Clear, along with expected CMS coverage progress for Northstar Response and continued salesforce expansion, creates a credible catalyst path for sustained growth and margin durability.

BillionToOne is vulnerable to a combination of competitive, legal, and operational pressures that could erode its position in molecular diagnostics, especially as it competes against larger prenatal and oncology players with established market share. Its revenue base depends heavily on test reimbursement and complex claim processing, so any billing compliance issues or Medicare/state Medicaid reimbursement setbacks could directly impair growth and cash generation. Although management still projects revenue rising to $456M in 2026, $580M in 2027, and $780M in 2028, rising operating expenses to $293M, $355M, and $438M, respectively, and modest margin compression underscore the challenge of translating volume growth into durable profitability.